Form 4: Kymera Therapeutics' Chief Legal Officer Reports Stock Transactions

Ellen Chiniara, Chief Legal Officer of Kymera Therapeutics, reports acquisition and disposal of common stock and stock options on March 3, 2025, including sales to cover tax obligations related to vesting RSUs.

Summary

• On March 3, 2025, Ellen Chiniara, the Chief Legal Officer of Kymera Therapeutics, reported transactions involving the company's common stock and stock options.
• Chiniara acquired 27,500 shares of common stock through restricted stock units (RSUs) at a price of $0.
• She also disposed of 1,833 shares at an average price of $30.3271 and 408 shares at an average price of $31.0046 to cover tax withholding obligations related to the vesting of RSUs.
• Following these transactions, Chiniara beneficially owns 80,085 shares of common stock.
• Additionally, Chiniara acquired options to purchase 55,000 shares of common stock at an exercise price of $30.17, which vest in 36 equal monthly installments starting March 3, 2025, expiring on March 2, 2035.
• After the reported transactions, Chiniara owns 55,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares through RSUs and stock options suggests confidence, while the sale of shares for tax obligations is a routine event.

Positives

• Acquisition of 27,500 shares through RSUs indicates confidence in the company's future.
• Grant of options for 55,000 shares aligns the executive's interests with those of shareholders.

Negatives

• Sale of shares to cover tax obligations, while routine, slightly reduces the executive's holdings.

Risks

• The vesting of RSUs and stock options is contingent upon continued employment, creating a potential risk if the executive leaves the company.

Future Outlook

The vesting schedules for RSUs and stock options suggest a commitment from the executive to remain with the company for the foreseeable future.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and RSU awards are common compensation practices in the biotechnology industry, used to attract and retain talent.
• Vesting schedules of three years for RSUs and three years for stock options are fairly standard in the industry.
• Comparing the size of the option grant (55,000 shares) to similar companies would require analyzing the company's compensation policies and benchmarking against peer companies.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding insider activity.
• The vesting schedules incentivize the executive to contribute to the company's long-term success.

Key Dates